Targeting chemotherapy with 70-gene MammaPrint signature in patients 60 years or younger with node-negative breast cancer is likely to be cost-effective.
Er Chen, MPP
Advertisement
Articles by Er Chen, MPP
Advertisement
Latest Updated Articles
- Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast Cancer
Published: December 21st 2010 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Team-Based Precision Oncology: Advancing Value and Access in Cancer Care
2
Navigating Costs and Logistics of Cellular Therapies, ADCs, and Novel Diagnostics in Cancer Care
3
From HIV Treatment Switching to Disease Prevention
4
Meeting the Needs of Patients With HIV: Virologic Suppression and the Expanding Treatment Landscape
5
